Postvaccination Bullous Pemphigoid in Infancy: Report of Three New Cases and Literature Review

Fuente, Sonia de la; Hernández‐Martín, Ángela; Lucas, R. de; González-Enseñat, M.A.; Vicente, A.; Colmenero, Isabel; González‐Beato, M.J.; Suñol, Mariona; Torrelo, Antonio

doi:10.1111/pde.12231

Cited by 37 publications

(27 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Approximately 20 cases of childhood BP reported in the literature occurred after vaccination. The tetanus, diphtheria, pertussis, and polio vaccine was administered in all cases, although in some patients, vaccinations against pneumococcus, Hemophilus influenzae B, hepatitis B, and Meningococcus were also administered and cannot be excluded as triggering factors .…”

Section: Discussionmentioning

confidence: 99%

Spectrum of Clinical Responses to Therapies in Infantile Bullous Pemphigoid

Taquin¹,

Chiavérini

Lacour³

2016

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Spectrum of Clinical Responses to Therapies in Infantile Bullous Pemphigoid

Taquin¹,

Chiavérini

Lacour³

2016

Pediatric Dermatology

View full text Add to dashboard Cite

show abstract

“…It is thought to be triggered after routine vaccinations, albeit very rare. 26,27 Clinically, genital involvement is more common in children older than 1 yo, whilst infants less than 1 yo are more likely to develop acral blistering, especially of the face, palms and soles. 28 Childhood BP responds rapidly to systemic steroids with low relapse rates and good prognosis (Figs.…”

Section: Uv Light Radiation and Infections Such As Human Herpes Virumentioning

confidence: 99%

Review of autoimmune blistering diseases: the Pemphigoid diseases

Daniel

Murrell

2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

Autoimmune Blistering Diseases of the Pemphigoid type is characterised by sub‐epidermal blisters (SEB) with circulating autoantibodies against components of the basement membrane zone (BMZ). The main disorders to date include bullous pemphigoid (BP), pemphigoid gestationis, mucous membrane pemphigoid (MMP), epidermolysis bullosa acquisita (EBA), linear IgA disease (LABD), dermatitis herpetiformis (DH), lichen planus pemphigoides and bullous lupus. This is in contrast to pemphigus and related disorders, which demonstrate intraepidermal acantholysis and a positive Nikolsky sign. The classification and management is based on clinical, histological and direct and indirect immunofluorescence findings. There are, however, overlapping clinical and histological features between the conditions and clinical heterogeneity within each disease.

show abstract

“…Immunizations have been anecdotally reported to precede the development of immunobullous diseases. 22,23,35,36 Because of the rarity and possible coincidental timing of these events, we did not weigh this heavily when developing the above guidelines. However, these previous observations do underscore the complex interactions of protective immunity and autoimmunity.…”

Section: Discussionmentioning

confidence: 99%

“…14 Rarely, pemphigus and (childhood) pemphigoid have reportedly developed after hepatitis B immunization. 35,36…”

Section: Hepatitis B Vaccinementioning

confidence: 99%

Literature‐based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses

2015

View full text Add to dashboard Cite

Autoimmune bullous diseases, such as pemphigus, pemphigoid, and dermatitis herpetiformis, are uniquely associated with vulnerability in the mucocutaneous barrier against infection. The management of immunobullous diseases is complex and may at times require immunosuppressive medications. Iatrogenic immunosuppression may increase susceptibility to vaccine-preventable illnesses. Currently, there are no guidelines to assist the clinician treating patients with immunobullous disease regarding the delivery of various vaccinations. The aim of this review is to provide recommendations for immunization in the unique setting of immunobullous disease. Recommendations are based on careful review of the literature in other conditions requiring iatrogenic immunosuppression, as well as the most recent Centers for Disease Control and Prevention guidelines. Immunization with nonlive vaccines appears to be a safe and effective strategy for preventing infection in the particularly susceptible patient with immunobullous disease. Opportunities for live vaccine administration may become available at lower levels of immune suppression or during clinical remission when immunosuppressive regimens can be reduced. Anticipatory vaccination before the initiation of iatrogenic immunosuppression is ideal. Although immunologic response to vaccination may be suboptimal during immunosuppression, nonlive vaccination is strongly recommended for this patient population.

show abstract

Postvaccination Bullous Pemphigoid in Infancy: Report of Three New Cases and Literature Review

Cited by 37 publications

References 11 publications

Spectrum of Clinical Responses to Therapies in Infantile Bullous Pemphigoid

Spectrum of Clinical Responses to Therapies in Infantile Bullous Pemphigoid

Review of autoimmune blistering diseases: the Pemphigoid diseases

Literature‐based immunization recommendations for patients requiring immunosuppressive medications for autoimmune bullous dermatoses

Contact Info

Product

Resources

About